Population growth and ageing are associated with an increase in global ozone-related mortality by a factor of 5
After exclusion of studies with critical bias, the pooled RR for COVID-19 mortality was 1
Hydroxychloroquine treatment appears to have no increased risk in the short term among patients with rheumatoid arthritis, but in the long term it appears to be associated with excess cardiovascular mortality
The study said hydroxychloroquine “did not significantly improve clinical status at day 14″ among hospitalized patients with respiratory illness from COVID-19
The antimalaria drug hydroxychloroquine has generated significant controversy
The study showed that in a short-term period (up to 30 days) after first use of hydroxychloroquine treatment in combination with azithromycin there was an increased risk of angina or chest pain Our meta-analysis showed that HCQ was not associated with a significant reduction or increase in the COVID-19 mortality rate
54, n = 7), indicating an increased mortality linked to the use of hydroxychloroquine with azithromycin
27; 95% CI, 1
04-1
Hydroxychloroquine with azithromycin was associated with an increased mortality (RR = 1
Conclusion: Hydroxychloroquine alone was not associated with reduced mortality in hospitalized COVID-19 patients but the combination of hydroxychloroquine
The aim of this study was to investigate whether hydroxychloroquine increases new-onset arrhythmia among patients with RA, SLE or SS
16), while among the unpublished trials there was no such sign of increased mortality (OR 0
” Indeed the data show a trend towards increased mortality in those given hydroxychloroquine, since the lower 95% confidence bound for the hazard ratio is only